Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11516807 | 0.98 | RAB9A (0.50) | RAB9AALDH1A1POLBLMNAPRCP | |
| Hydrochloric Acid SCHEMBL1978418 | 0.98 | RAB9A (0.50) | RAB9AALDH1A1POLBLMNAPRCP | |
| SCHEMBL4004258 | 0.77 | RAB9A (0.56) | RAB9AALDH1A1POLBLMNA | |
| Hydrochloric Acid SCHEMBL7529821 | 0.75 | RAB9A (0.54) | RAB9AALDH1A1POLBLMNA | |
| SCHEMBL12312207 | 0.72 | PRCP (0.41) | RAB9AALDH1A1POLBPRCP | |
| SCHEMBL6420198 | 0.72 | LMNA (0.72) | RAB9AALDH1A1POLBLMNAPRCP | |
| SCHEMBL10297542 | 0.71 | RAB9A (0.39) | RAB9AALDH1A1POLBLMNAAOC3 | |
| Hydrochloric Acid SCHEMBL21751204 | 0.71 | PRCP (0.40) | RAB9AALDH1A1POLBPRCP | |
| SCHEMBL4762153 | 0.69 | RAB9A (0.51) | RAB9AALDH1A1POLBLMNA | |
| SCHEMBL3441643 | 0.68 | RAB9A (1.00) | RAB9AALDH1A1POLBLMNAPRCP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040969-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2021-06-22 | — | — | US | disclosed |
| US-10399973-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2019-09-03 | — | — | US | disclosed |
| US-20180118744-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9890160-B2 | Compounds I | PROXIMAGEN LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-20170044157-A1 | NEW COMPOUNDS I | PROXIMAGEN, LLC | 2017-02-16 | — | — | US | disclosed |
| US-9493457-B2 | 4,5,6,7-tetrahyroimidazo[4,5-c]pyridine compounds | PROXIMAGEN LIMITED (GB) | 2016-11-15 | — | — | US | disclosed |
| US-20150218161-A1 | NEW COMPOUNDS I | PROXIMAGEN, LLC | 2015-08-06 | — | — | US | disclosed |
| US-9035066-B2 | Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds | PROXIMAGEN LIMITED (GB) | 2015-05-19 | — | — | US | disclosed |
| US-20140121219-A1 | New Compounds I | PROXIMAGEN LIMITED (GB) | 2014-05-01 | — | — | US | disclosed |
| EP-2334672-B1 | 4,5,6,7-Tetrahydroimidazo[4,5-c]pyridine compounds as inhibitors of SSAO | PROXIMAGEN LTD (GB) | 2013-11-20 | — | — | EP | disclosed |
| US-8569338-B2 | Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds | PROXIMAGEN LTD. (GB) | 2013-10-29 | — | — | US | disclosed |
| US-20120302583-A1 | New Compounds I | PROXIMAGEN LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8263616-B2 | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds | PROXIMAGEN LTD (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20110207746-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| EP-2334672-A1 | NEW COMPOUNDS I | Proximagen Limited (GB) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010031789-A1 | NEW COMPOUNDS I | BIOVITRUM AB (PUBL) (SE) | 2010-03-25 | — | — | WO | disclosed |
| US-4141899-A | ANTIULCER, ANTISECRETORY | SOCIETA' FARMACEUTICI ITALIA S.P.A. (IT) | 1979-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10399973-B2 | Compounds I | SSB, SQLE, ALOX15B | RAB9A 3829/4885ALDH1A1 247/4885POLB 866/4885 |
| US-20110207746-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | RAB9A 3695/4885ALDH1A1 253/4885POLB 812/4885 |
| US-20120302583-A1 | New Compounds I | SSB, NFKBIA, NOD1 | RAB9A 3917/4885ALDH1A1 724/4885POLB 1251/4885 |
| US-11040969-B2 | Compounds I | SSB, SQLE, ALOX15B | RAB9A 3829/4885ALDH1A1 247/4885POLB 866/4885 |
| US-20140121219-A1 | New Compounds I | SSB, NFKBIA, ALOX15B | RAB9A 3695/4885ALDH1A1 253/4885POLB 812/4885 |
| US-20170044157-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | RAB9A 3695/4885ALDH1A1 253/4885POLB 812/4885 |
| US-20180118744-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | RAB9A 3695/4885ALDH1A1 253/4885POLB 812/4885 |
| US-20150218161-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | RAB9A 3695/4885ALDH1A1 253/4885POLB 812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.